Adaptive Biotechnologies CPO Francis Lo sells $3.2m in stock

Chief People Officer at Adaptive Biotechnologies, Francis Lo, divested $3.2 million worth of company stock on September 16, 2026. The shares were sold at prices ranging from $27.49 to $28.67 through a pre-established Rule 10b5-1 trading plan initiated on September 15, 2025. Concurrently, Lo purchased 105,560 shares of common stock via the exercise of stock options, amounting to $1.01 million.

The exercise prices for these options fluctuated between $3.99 and $12.14 per share, with some options being fully vested while others had varied vesting schedules. Lo's insider sale occurred as Adaptive Biotechnologies shares hovered near their 52-week peak of $28.72, generating a notable 114% return over the past year. InvestingPro analysis suggests the stock is currently overvalued at a high Price/Book multiple of 31.96.

Post-transaction, Lo directly owns 220,867 shares of Adaptive Biotechnologies, with an additional 2,500 shares indirectly held through his spouse, You Jin Lee. Lo also maintains various stock options to acquire further shares. Recently, Adaptive Biotechnologies reported an adjusted loss of $0.25 per share in its second quarter, failing to meet the $0.14 loss per share consensus estimate.

However, the company's revenue of $71.6 million exceeded the $65.8 million analyst estimate, marking a 22% increase from $58.7 million in the same quarter last year. BTIG raised its price target for Adaptive Biotechnologies shares to $25 from $24, retaining a Buy rating. The firm commended the company's 49% year-over-year revenue growth in its minimal residual disease business, excluding milestones, and volume growth in the clonoSEQ MRD test franchise at 43% year-over-year.